

CUMULATIVE ANTIMICROBIAL SUSCEPTIBILITY PROFILES

2010 (January to December)

ST. JOSEPH HOSPITAL ORANGE, CA	Penicillin	Ampicillin	Methicillin	Cefazolin	Ceftriaxone	Cefepime	Piperacillin /tazobactam	Imipenem	Ciprofloxacin	Levofloxacin	Vancomycin	Daptomycin	Linezolid	Gentamicin	Tobramycin	Amikacin	Clindamycin	Trimeth / Sulfa	Tetracycline	Nitrofurantoin ³	Total # of Isolates
	% SUSCEPTIBLE																				
Escherichia coli ²		48		89	98	99	96	100	76	76				90	91	99		68		97	1680
Escherichia coli ESBL							83	100	8	8				67	28	89		36		85	84
Enterobacter cloacae					84	94	91	97	96	97				96	94	98		87		30	99
Klebsiella pneumoniae ²					99	99	96	100	94	95				98	97	98		90		47	276
Klebsiella pneumoniae ESBL							37	100	0	0				40	18	43		0		11	16
Proteus mirabilis ²					99	100	99	98	65	75				89	91	99		74		0	208
Pseudomonas aeruginosa						89	92	90	73	72				82	92	96					329
Serratia marcescens					97	97	83	95	87	97				100	93	100		97		0	48
Staphylococcus aureus (MRSA and MSSA)			58	58						50	100	100	100				67	99			710
Staphylococcus aureus MRSA										8	100	100	100				49	99	95		295
Coagulase negative Staphylococcus			37	37						50	100	100	100				65		81		529
Staphylococcus epidermidis			30	30						43	100	100	100				59		80		62
Streptococcus pneumoniae	75 ¹				85 ¹					100											33
Enterococcus sp. (includes E. faecalis, E. faecium)											88	100	99								605

Notes:

¹ Meningitis dose interpretation (Strep. pneumoniae)

² E.coli, Klebsiella & Proteus data do NOT include organisms with ESBL (reported separately)

³ Urinary isolates only

The data presented are for informational purposes only and must be utilized in conjunction with clinical interpretation.

Data source: SafetySurveillor (only first patient isolate in 2010 counted)